The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Fimepinostat with venetoclax in R/R lymphoma
Anas Younes, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, outlines the interesting synergistic anti-tumor effects of fimepinostat (CUDC-907), a dual inhibitor of phosphotidyl-inositol-3-kinases (PI3Ks) and Class I and II histone deacetylases (HDACs), in combination with venetoclax, a BCL2 inhibitor. This novel combination targeting MYC and BCL2 was recently evaluated in a phase 1/2, multi-center, dose-finding trial (NCT01742988), in patients with relapsed/refractory (R/R) lymphoma, R/R diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 alterations. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
